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Abstract  43 
Volitional neural modulation using neurofeedback has been indicated as a potential 44 
treatment for chronic conditions that involve peripheral and central neural 45 
dysregulation. Here we utilized neurofeedback in patients suffering from 46 
Fibromyalgia - a chronic pain syndrome that involves sleep disturbance and emotion 47 
dysregulation. These ancillary symptoms, which have an amplification effect on pain, 48 
are known to be mediated  by heightened limbic activity. In order to reliably probe 49 
limbic activity in a scalable manner fit for EEG-neurofeedback training, we utilized 50 
an Electrical Finger Print (EFP) model of amygdala-BOLD signal (termed Amyg-51 
EFP), that has been successfully validated in our lab in the context of volitional 52 
neuromodulation. 53 
 54 
We anticipated that Amyg-EFP-neurofeedback training aimed at limbic down 55 
modulation should improve chronic pain in patients suffering from Fibromyalgia, by 56 
balancing disturbed indices for sleep and affect. We further expected that improved 57 
clinical status would correspond to successful training as indicated by improved down 58 
modulation of the Amygdala-EFP signal. 59 
 60 
Thirty-Four Fibromyalgia patients (31F; age 35.6±11.82) participated in a randomized 61 
placebo-controlled trial with biweekly Amyg-EFP-neurofeedback sessions and 62 
placebo of sham neurofeedback (n=9) for a total duration of five consecutive weeks. 63 
Following training, participants in the Real-neurofeedback group were divided into 64 
good (n=13) or poor (n=12) modulators according to their success in the 65 
neurofeedback training. Before and after treatment, self-reports on pain, depression, 66 
anxiety, fatigue and sleep quality were obtained, as well as objective sleep Indices. 67 
Long-term clinical follow-up was made available, within up to three years of the 68 
neurofeedback training completion.    69 
 70 
REM latency and objective sleep quality index were robustly improved following the 71 
treatment course only in the Real-neurofeedback group (both time*group p<0.05) 72 
and to a greater extent among good modulators (both time*sub-group p<0.05). In 73 
contrast, self-report measures did not reveal a treatment-specific response at the end 74 















in chronic pain and subjective sleep experience, evident only in the Real-76 
neurofeedback group (both time*group p<0.05). Moderation analysis showed that the 77 
enduring clinical effects on pain evident in the follow-up assessment were predicted 78 
by the immediate improvements following training in objective sleep and subjective 79 
affect measures.  80 
 81 
Our findings suggest that Amyg-EFP- neurofeedback that specifically targets limbic 82 
activity down modulation offers a successful principled approach for volitional EEG 83 
based neuromodulation training in Fibromyalgia patients. Importantly, it seems that 84 
via its immediate sleep improving effect, the neurofeedback training induced a 85 
delayed reduction in the target subjective symptom of chronic pain, far and beyond 86 
the immediate placebo effect. This indirect approach to chronic pain management 87 
reflects the necessary link between somatic and affective dysregulation that can be 88 
successfully targeted using neurofeedback. 89 
















 Highlights 92 
• Fibromyalgia patients were trained in limbic neuromodulation 93 
• After training, only Real-NF group showed improvement in objective sleep 94 
measures 95 
• Follow-up revealed group specific improvement in pain and subjective sleep 96 
• Pain alleviation was moderated by initial improvement in objective sleep and 97 
affect 98 
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1. Introduction 114 
 115 
Volitional neuromodulation, known as neurofeedback (NF), allows individuals to 116 
exert control over neural activity by bridging between mental states and neural signal 117 
modulation (Sitaram et al., 2017). Such bridging may be necessary to preserve 118 
somatic-affective homeostasis; maintaining stability of the internal bodily 119 
environment and related subjective experience in response to environmental 120 
challenges (Barrett and Simmons, 2015).  121 
Chronic somatic disorders involve impaired homeostatic regulation that is mediated 122 
by disturbed neural function (Di Lernia et al., 2016a; Elman and Borsook, 2016; 123 
Smallwood et al., 2013).  It has been suggested that NF can be used to modulate 124 
neural probes supporting homeostatic regulation, and may therefore be particularly 125 
suitable  for treating somatic-affective homeostasis related disorders such as insomnia 126 
and chronic pain (Arns and Kenemans, 2014; deCharms et al., 2005). However it 127 
remains unclear to what extent the NF effects demonstrated in such disorders are 128 
mediated by improved homeostasis, as opposed to non-specific, placebo-like 129 
processes (Thibault et al., 2016).  130 
Fibromyalgia is a highly prevalent and difficult to treat chronic pain syndrome 131 
characterized by widespread pain, intimately related to maladaptive homeostatic 132 
processes of sleep and emotion regulation (Choy, 2015; Hamilton et al., 2008; Hassett 133 
et al., 2008 Häuser et al., 2015). he pain chronicity in Fibromyalgia was suggested to 134 
be a multistep process that involves the breakdown of several control mechanisms, 135 
mainly mood regulation and sleep quality (Choy, 2015). In accordance, 136 
manifestations of aberrant sleep in Fibromyalgia and related disorders include 137 
increased sleep latency, reduced sleep efficiency (Diaz-piedra et al., 2014), decreased 138 
REM latency, increased REM percent  (Moldofsky, 2001; Riemann, 2007) and 139 
reduced deep sleep periods (Choy, 2015). Chronic impairments in sleep have thus 140 
been suggested to result in enhanced “allostatic load”-the increased energetic 141 
expenditure an organism is required to endure as a result of being forced to adapt to 142 
adverse psychosocial or physical situations (McEwen, 2000, 2006; Sapolsky, 2007). 143 
This allostatic accumulation may lead to further neural, physiological and behavioral 144 















(Borsook et al., 2012). Accordingly, Fibromyalgia is considered a prototype of the 146 
"central sensitization syndrome"; hypersensitivity of the central nervous system that is 147 
assumed to underlie a spectrum of complex psychiatric and somatic conditions 148 
including: posttraumatic stress disorder (PTSD), migraine headache and premenstrual 149 
dysphoric disorder (Yunus, 2008, 2007). The common denominator of these disorders 150 
could be impaired homeostasis manifested in sleep disturbance and emotion 151 
dysregulation  .  152 
A key factor regulating both sleep and emotion is the amygdala (Goldstein-Piekarski 153 
et al., 2015; Wager et al., 2008). Indeed, Fibromyalgia patients display altered limbic 154 
functionality as indicated by neural activity and connectivity studies (Cifre et al., 155 
2012; Dehghan et al., 2016; Jensen et al., 2012) as well as reductions in gray matter 156 
volume within the amygdala (Burgmer et al., 2009; Lutz et al., 2008). Interestingly, 157 
limbic abnormalities have also been demonstrated in sleep deprivation (Simon et al., 158 
2015; Yoo et al., 2007) as well as in "central sensitization syndrome" disorders such 159 
as PTSD (Hendler et al., 2003; Shin et al., 2006). We therefore hypothesized that 160 
neuromodulation of limbic activity using NF would serve as a good target for patients 161 
suffering from Fibromyalgia.   162 
 163 
Numerous studies have demonstrated that using real-time fMRI-NF, healthy 164 
individuals can successfully modulate their limbic activity and present behavioral 165 
changes related to the targeted brain probe (for review see Sitaram et al., 2017). 166 
Clinical studies have further demonstrated similar results using amygdala driven 167 
fMRI-NF across several homeostatic/central sensitization disorders such as PTSD 168 
(Nicholson et al., 2017), borderline personality disorder (Paret et al., 2016) and 169 
major depression (Young et al., 2017a, 2017a).    170 
In chronic pain, two studies examined the efficacy of rt-fMRI-NF by targeting 171 
the rACC (rostral Anterior Cingulate Cortex); a major node in the affect aspect 172 
of the pain matrix (deCharms et al., 2005; Guan et al., 2015). Results of these 173 
studies showed an improvement in ongoing pain following rt-fMRI-NF training, 174 
claiming an effect of rACC down regulation on pain perception. However, due to 175 
small sample sizes in both studies and at least in one study (i.e. deCharms et al., 176 
2005), lack of replication and proper control  (deCharms, 2012), the clinical 177 
benefit of NF for chronic pain should be supported by further evidence (Jensen 178 

















 Despite the potential of this treatment option, the high cost of real-time fMRI NF 182 
severely limits its use in community settings. Even when available, the number of 183 
training sessions for each individual ends up being restricted by equipment 184 
availability. Moreover, traditional criteria for MRI compatibility may result in the 185 
exclusion of a significant subset of patients. To overcome such difficulties, we 186 
recently introduced a novel approach that combines the advantages of fMRI and EEG, 187 
i.e., high anatomical resolution and widespread availability, respectively. Our 188 
technology is based on an fMRI-driven EEG computational model, that reflects 189 
amygdala activation and supporting regulation networks (i.e. limbic and salience 190 
systems) as depicted in simultaneous EEG/fMRI recording, termed here 191 
"Amygdala-Electrical Fingerprint" (Amyg-EFP) (Keynan et al., 2016; Meir-192 
Hasson et al., 2016, 2014). In a series of validation studies on a separate group of 193 
healthy participants, we have shown that NF training employing the Amyg-EFP signal 194 
as a probe, resulted in improved targeting of the amygdala BOLD (Blood-oxygen-195 
level dependent) signal in a subsequent fMRI session  (Keynan et al., 2016). Feather, 196 
we have recently demonstrated that repeated session Amyg-EFP-NF resulted in 197 
improved emotion regulation as well as enhanced amygdala-BOLD down 198 
regulation and amygdala-vmPFC functional connectivity (Keynan et al., 199 
Accepted) 200 
 201 
Utilizing Amyg-EFP for the first time in the clinical domain we have now conducted 202 
a multisession, double-blind, placebo-controlled NF trial in patients suffering from 203 
Fibromyalgia. The goal was to train individuals to down-modulate the Amyg-EFP 204 
signal and to examine the training effect on chronic pain as well as on ancillary 205 
symptoms related to somatic and affective regulation. We obtained subjective 206 
assessment of pain, sleep and affect dysregulation, as well as objective measures of 207 
sleep quality. Of the numerous manifestations of aberrant sleep in Fibromyalgia,  our 208 
focus was on REM latency, which is  known to be related to amygdala activation 209 
(Luppi et al., 2004; Nofzinger et al., 2004) and affective dysregulation in mood 210 
















We hypothesized that: (1) Fibromyalgia patients in the Real-NF group would exhibit 213 
greater down modulation of the Amyg-EFP signal than the control group. (2) Given 214 
that our training probe was limbic and not classically related to the core pain 215 
processing network (Apkarian et al., 2005), we expected that the Amyg-EFP-NF 216 
training would differentially improve ancillary symptoms related to homeostasis as 217 
demonstrated by sleep and affect impairments. Moreover, we expected these changes 218 
to be accompanied by improvement in chronic pain symptoms. (3) Individual 219 

















2. Materials and methods 223 
 224 
2.1 Participants 225 
Patients were recruited from the Fibromyalgia clinic of the Institute of Rheumatology 226 
and from the Institute of Pain Medicine at Tel Aviv Medical Center in Israel. All 227 
patients had a diagnosis of Fibromyalgia according to the American College of 228 
Rheumatology (ACR) 2010 criteria (Wolfe et al., 2011) which was confirmed by a 229 
clinical interview and physical examination by an expert rheumatologist or pain 230 
specialist. Exclusion criteria included other chronic pain syndromes, major 231 
neuropsychiatric illness and recently changed/initiated pharmacotherapy. Patients 232 
were randomly assigned using a computerized algorithm to either sham-EFP or true 233 
NF interventions, with an a-priori ratio of 1:2 favoring the latter. This ratio was 234 
determined in order to allow for subgrouping of the true intervention group into good 235 
and poor NF modulators. Blinding was performed using in-house computer software 236 
and a file containing participant's group affiliation was examined only when NF data 237 
collection had ended. Thus, participants, care providers and clinicians assessing 238 
outcomes were all blinded to treatment. 239 
In total, 136 FM patients underwent initial screening during which ninety-three 240 
subjects were excluded:  seventy-four did not wished to participate for various 241 
personal reasons and nineteen did not meet the ACR 2010 criteria. Forty-three 242 
participants underwent randomization and were allocated randomly to real or 243 
sham NF intervention. This resulted in 31 participants randomly allocated to the 244 
real NF group and 12 participants allocated to the sham group (in total n=43). Of 245 
the 31 participants that were allocated to the real NF group, 6 dropped out 246 
voluntarily, resulting in 25 participants (24 females) that underwent the full real 247 
Amyg-EFP NF treatment.Of the 12 participants allocated to the sham NF group, 248 
3 dropped out voluntarily, resulting in 9 (7 females) participants that underwent 249 
the full sham NF treatment, totaling 34 FM patients who completed the main 250 
procedure (age=35.62±6.1, 31 females, 79% retention, see table 1).  251 
 252 















Treatment study: The study was conducted at the Sagol Brain Institute, Tel Aviv 254 
Sourasky Medical Center and was approved by the Institutional Ethical Review 255 
Board. All participants provided written informed consent before entering the study. 256 
Prior to the NF treatment course, patients underwent a “pre-NF” (pre) assessment that 257 
included a clinical evaluation, disease-related questionnaires, and one night of home 258 
sleep monitoring using an ambulatory sleep device (WatchPAT-200; Itamar Medical). 259 
Patients then underwent ten biweekly sessions of either Real-NF or sham-EFP. After 260 
completing the NF course patients underwent “Post NF” (post) assessment, conducted 261 
within one week of the last NF session. This evaluation was identical to the baseline 262 
assessment (see Fig. 1).  263 
 264 
Follow-up assessment: As part of a new study, examining the feasibility of a new 265 
NF technique, we re-contacted subjects who participated in the study. We were 266 
able to reach 32 subjects 16.2±8.72 months following completion of NF training 267 
(Real-NF group=23, the two participants who did not complete follow-up were in 268 
the "good modulators" subgroup, for details regarding characteristics of this 269 
sample see Table S2). We used this opportunity for an exploratory assessment of 270 
long-term effects of the Real-Intervention using the same outcome questionnaires (see 271 
outcome measures). Notably, during the time of this follow up, subjects were still 272 
blinded to the type of treatment they received (real or sham- NF). Of note, all 273 
analyses of the follow-up assessment included time from the end of treatment as a 274 
covariant to account for variability across participants (see Statistical analysis).  Also 275 
at this time point, no marked difference in pharmacological treatment were 276 
observed between real NF and sham groups (see Table S2).  277 
 278 
2.3 Neurofeedback procedure  279 
NF treatment course protocol included ten NF sessions, each session was composed 280 
of training either using an auditory interface (sessions one, three and five), an 281 
animated scenario interface (sessions two, four and six) or both (sessions seven, 282 
eight nine and ten in the same order across sessions) (see Fig S1A). Missing more 283 
than two NF sessions, out of a total of ten, was determined as a criterion for 284 















Patients were trained to downregulate their Amyg-EFP using two interfaces for 286 
feedback: 1. An auditory interface in which the neural signal correlated with the 287 
volume  of a soft piano tune (Kinreich et al., 2014), and 2. A 3D audio-visual 288 
animated scenario in which the neural signal is correlated with the level of unrest in a 289 
scenario where virtual characters in a waiting room become impatient, leave their 290 
seats and gesture loudly at the front desk receptionist (Cohen et al., 2016) (for 291 
illustration see Fig S1B).The decision to use two different interfaces aimed to 292 
encourage broad exploration of mental strategies, which can potentially lead to 293 
better regulation abilities. As the advantage of multi-modal stimuli has been 294 
demonstrated in various contexts of perceptual learning (Gibson and Maunsell, 295 
1997; Kriegstein and Giraud, 2006; Shams and Seitz, 2008) and were suggested  296 
to strengthen integrative processes (van Atteveldt et al., 2014), we decided to 297 
introduce participants to varied feedback environments that would potentially 298 
maximize their regulation performance. Within each session, NF trials contained 299 
two conditions: rest and regulate.  Participants were instructed to modulate the 300 
interface only during the regulate condition. The Real-NF group received feedback 301 
reflecting their Amyg-EFP signal level modulation while the control group received 302 
feedback reflecting a pre-recorded Amyg-EFP signal obtained from another 303 
successful participant in the Real-NF group, indicating approximately 85 percent 304 
success in each session. EFP signal for the sham NF condition was obtained from 305 
different participants in accordance with the relevant order of sessions and feedback 306 
modality. This method of producing a sham signal enabled us to control for “NF 307 
general effects” such as control (applying mental strategies in the attempt to 308 
modulate the presented neural pattern), reward (valuation of positive/negative 309 
outcomes of applied strategies) and Learning (the consolidation of associations 310 
between reward feedback cues and neural activity patterns) (Sitaram et al., 311 
2017). 312 
 313 
2.4 EEG acquisition and on-line calculation  314 
EEG data was acquired using the V-Amp™ EEG amplifier (Brain Products™, 315 
Munich Germany) and the BrainCap™ electrode cap with sintered Ag/AgCI ring 316 
electrodes (Falk Minow Services™, Herrsching-Breitburnn, Germany). Electrodes 317 















between Fz and Cz. Raw EEG signal was sampled at 250 Hz and recorded using the 319 
Brain Vision Recorder™ software (Brain Products). Amyg-EFP amplitude was 320 
calculated based on data recorded from the Pz channel using an in-house algorithm 321 
(Meir-Hasson et al., 2016, 2014). See supplementary material for more details.  322 
 323 
2.5 NF success measure 324 
 325 
Similar to in previous studies (Cohen et al., 2016), success in Amyg-EFP signal 326 
downregulation was assessed by calculating a personal effect size (Cohen’s d) of each 327 
subject in each trial using the following formula:  328 
Effect size=  329 
As the neural target was Amyg-EFP down regulation, a desired result would be lower 330 
“regulate” than “rest” values, resulting in a bigger (more positive) effect size (see Fig.  331 
S1C  for a graphic description)   332 
Overall success (across all sessions) was evaluated using a global NF score: we first 333 
calculated z-scores for the effect size for each NF session for each interface. Using 334 
these z-scores, we then calculated the mean effect size across all sessions.  335 
In order to assess the contribution of success in NF to changes in clinical status, 336 
we wished to cluster the real-NF group into two subgroups based on their 337 
performance. Clustering was based on relative difference within the real-NF 338 
group. To this end, we used the popular k-means algorithm that clustered the 339 
two subgroups based on effect sizes from all the sessions. This clustering was 340 
further validated by median split of the global NF score, resulting in two sub-341 
groups: good (n=13, 13 female) and poor (n=12, 11 female) modulators.  To assess 342 
the improvement in NF learning over sessions we calculated the delta between the 343 
normalized effect size in the first and last sessions in both interfaces. This was labeled 344 
the NF learning index.  345 
 346 
2.6 Outcome Measures 347 
Self-report measures: In order to assess the patient’s condition in  three core 348 
symptoms of Fibromyalgia (pain, sleep experience and affect) we used the following 349 















(Burckhardt et al., 1991),  trait anxiety inventory (STAI-T) (Spielberger et al., 1970), 351 
Beck depression inventory (BDI) (Beck et al., 1961), the Pittsburgh sleep quality 352 
index (PSIQ) (Buysse et al., 1989) and the McGill pain questionnaire (Melzack, 353 
1975), which also includes a Visual Analogue Scale (VAS). To tackle the overlap 354 
evident across these questionnaires, three compound scores were computed from all 355 
subscales reflecting pain, sleep experience, and affect. The compound scores were 356 
based on reliability tests, indicating the overall consistency of a measure by 357 
representing the proportion of systematic variation in a scale. Each scale was 358 
constructed using the combination of self-report scales that provided the highest 359 
reliability score, measured using Cronbach's alpha (Cronbach, 1951; Tavakol and 360 
Dennick, 2011). Affect was assessed using mean normalized score of the STAI-T 361 
questionnaire, the BDI questionnaire, and the anxiety and depression subscales of the 362 
FIQ questionnaire (Cronbach's alpha =0.76). Sleep experience was assessed using 363 
normalized score of the PSIQ and the fatigue subscale of the FIQ questionnaire 364 
(Cronbach's alpha =0.77). Pain was assessed using VAS and general score of the 365 
McGill pain questionnaire and subscales of the FIQ for pain (Cronbach's alpha=0.91). 366 
Sleep assessment: One-night sleep monitoring was performed up to one week before 367 
and after the NF training course using the WachPAT-200 device. This device is based 368 
on recordings of peripheral arterial tone, along with pulse rate, actigraphy, and pulse 369 
oximetry. The WachPAT-200 was shown to accurately detect sleep versus 370 
wakefulness (Hedner et al., 2004), to differentiate light and deep sleep, and to detect 371 
REM sleep (Bresler et al., 2008; Hedner et al., 2011; Herscovici et al., 2007).   372 
REM latency (i.e. time span between the start of sleeping and the start of the first 373 
REM episode) was used as the main sleep outcome measure due to prior work 374 
demonstrating a robust link between increased REM latency and mood regulation 375 
disorders (Palagini et al., 2013). To assess sleep more globally, we created an index 376 
composed of several features known to be important for sleep in Fibromyalgia. This 377 
index reflected increased sleep latency (time between going to bed and falling 378 
asleep), reduced sleep efficiency (the ratio of the total time spent asleep compared 379 
to the total amount of time spent in bed) and lack of proper deep sleep (quantified 380 
using "deep sleep percent" and "REM sleep percent", i.e. the ratio of the total 381 
time spent in deep/REM sleep out of the total sleep time)  (Spaeth et al., 2011). 382 















reflecting its contribution to the sleep abnormality in Fibromyalgia: sleep latency 384 
(-1), sleep efficiency (+1), REM latency (+1), deep sleep percent (+1) and REM sleep 385 
percent (-1). The average of these weighted and standardized scores was defined 386 
as the composite sleep score. 387 
 388 
 389 
2.7 Statistical analyses 390 
Analyses were performed using IBM SPSS, version 20, Statistica version 10 391 
(StatSoft, Inc) and MATLAB 2013b. Demographic results were descriptive and 392 
expressed as mean±standard deviation (see table.1). We compared the baseline 393 
characteristics of each group using chi-square or Fisher's exact test for categorical 394 
variables, and two-sample t-test for continuous variables. All reported p values are 395 
two tailed and Bonferroni corrected (Dunn, 1961) with respect to the number of 396 
comparisons conducted in each analysis, unless stated otherwise. 397 
Real-NF group  398 
2.7.2 Outcome measures 399 
To evaluate treatment effect, we used mainly repeated measures ANOVAs, with 400 
between-subject factor of group (Amyg-EFP-NF/sham-EFP). To evaluate NF 401 
learning we used NF session (first/last) as within-subject factor and for clinical 402 
improvement we used pre/post NF training within-subject factor.  403 
To assess the contribution of NF regulation abilities to the clinical outcome, we 404 
categorized the Real-NF group into two subgroups according to their success (see 405 
above). We then performed repeated measures ANOVA with clinical outcome as 406 
dependent variable, with three groups (good modulators/poor modulators and 407 
sham-EFP) as between subject factor and time (pre/post NF) as the within 408 
subject factor. 409 
When assessing clinical improvement at follow-up, a covariant of time from end of 410 
treatment was included in all statistical models. Treatment effects were tested at a 411 
two-sided significance level of 0.05. Change in outcome measures was quantified 412 
using effect size (Cohen's d) (Cohen, 1992, 1988).  413 
For clinical efficacy assessment, we evaluated the number needed to treat (NNT) for 414 
our primary objective sleep outcome measure, REM latency, and for pain reduction. 415 















benefit compared with a control (Laupacis et al., 1988). Thus, higher NNT indicates 417 
less effective treatment (Cordell, 1999). For normalized sleep, we defined clinical 418 
improvement as a patient that had a pre-assessment REM latency of less than 90 419 
minutes and post-NF assessment of more than 90 minutes. Reduced pain was defined 420 
as at least forty percent decrease in visual analog scale (VAS). 421 
2.7.3 Moderation analysis 422 
To examine whether reduction in pain ratings in the follow-up assessment was due to 423 
clinical changes observed at the end of the NF training, we used moderation analysis. 424 
This analysis determines whether the size of the effect of some putative causal 425 
variable X on outcome Y depends on a moderator variable (Hayes, A. F., 2013). In 426 
other words, how the interaction between two independent variables can contribute to 427 
the prediction of the outcome variable.  Specifically, we applied this concept to 428 
examine whether changes in composite sleep score moderate the manner by which 429 
initial improvement in extra-musculoskeletal symptoms (i.e. affect and sleep 430 
experience) impact pain improvement in the long run. For this moderation analysis we  431 
used the bootstrap method of Preacher and Hayes (Preacher and Hayes, 2004), which 432 
enabled estimation of the effects that composite sleep score (pre-post), affect (pre-433 
post), sleep experience (pre-post) and their interaction had on pain in the follow-up 434 
assessment (post-follow-up). This was done with time from the end of NF training as 435 
covariant.  We evaluated the contribution of composite sleep score as moderator and 436 
of each predictor separately, based on 5000 bootstrap samples using SPSS macro 437 

















3. Results 441 
 442 
3.1 Neurofeedback learning and success  443 
In accordance with our first hypothesis, we found improved performance in Amyg-444 
EFP regulation abilities in the last compared to the first training session in the Real-445 
NF, but not in the control group (Fig. 2A). A repeated measures ANOVA revealed 446 
greater NF learning in the Real-NF group compared to the control group 447 
[Session*Group interaction F(1,32)=9.7; p<0.005; d=1.24], with first-last session 448 
difference significant for the Real-NF group only [post hoc 449 
pBonferroni<0.0005].(for further details regarding results of NF learning see 450 
supplementary material) 451 
We then sought to examine whether performance during the first NF sessions 452 
were predictive of overall NF regulation performance. To this end, a regression 453 
model was built using Real-NF group data (n=25). The model’s aim was to predict 454 
the average effect size of sessions 3-10 using the first two NF sessions. To this 455 
end, two predicting variables were entered into the model: the effect size of the 456 
first animated scenario session and the effect size of the first auditory session. 457 
The final model contained only the animated scenario success index as a single 458 
predictor, as its predictive power had a more significant contribution. The 459 
auditory success index did not contribute significantly to the model and was thus 460 
excluded from its final version. The final model accounted for 16.5% (adjusted R 461 
square) of the variance in the dependent variable; overall regulation 462 
performance [F(1,24)=5.6;p<.05] (see Fig. 2B) 463 
. 464 
 465 
3.2 Neurofeedback training outcomes  466 
Our second hypothesis asserted that Real-NF training would improve homeostatic 467 
indices such as sleep and affect as well as measures of pain (for full details 468 
regarding clinical outcomes see supplementary table 1). Notably, one participant 469 
from the Real-NF group was not included in this analysis, as he did not provide 470 
self-report measures in the pre-assessment. Focusing first on subjective measures 471 















treatment (all Time*Condition p>0.16). Following our a-priori assumption, we 473 
nevertheless tested for the simple effect of time in each group. This analysis revealed 474 
two significant results: affect was improved in the Real-NF group only, and sleep 475 
experience was improved across both groups (p<0.01; p<0.005 respectively) (Fig. 3A-476 
C).     477 
In contrast, analysis of the objective measures of sleep: REM latency and composite 478 
sleep score (see methods), indicated greater improvement in real than sham-NF 479 
group after treatment. [Time*Condition interaction; REM latency: F (1,30) =4.43; 480 
p<0.05; d=0.85, composite sleep score: F (1,30)=6.81; p<0.05;d=1.05]. The NNT 481 
calculation for normalizing REM latency to at least ninety minutes, was 3.875.  Of 482 
note, two subjects were unable to perform one session of objective sleep assessment 483 
due to technical difficulties and were thus excluded from the analysis. The two 484 
missing datasets belonged to participants from the Real-NF group; one from the 485 
good modulators and one from the poor modulators subgroup. 486 
3.3 Neurofeedback success relation to clinical outcome 487 
Our third hypothesis predicted that individual differences in NF modulation would be 488 
reflected in clinical Real-NF group outcome. In contrast to our expectation, there 489 
was no significant Time*Sub-group interaction for affect, sleep experience or pain 490 
(all p>0.18). 491 
However, objective outcome measures confirmed our hypothesis for both REM 492 
latency [Time*Group, F(2,29)=4.46; p<0.05;d=1.15], and composite sleep score 493 
[Time*Group, F(2,29)=8.1; p<0.005; d=1.4], showing improvement over time only in 494 
good modulators [REM latency; pBonferroni<0.05, composite sleep score; 495 
pUncorrected<0.005]. We further computed a change index for REM latency and 496 
composite sleep score (the delta between the 'pre' and 'post' assessment) in order to 497 
confirm that improvement in objective sleep indices was greater in good modulators. 498 
We then used this index in a one-way ANOVA model.  This test confirmed that good 499 
modulators improved to a greater degree compared to both the poor modulators or 500 
sham group [REM latency, good modulators vs. sham; pBonferroni<0.05, composite 501 
sleep score, good modulators vs. sham; pBonferroni<0.005, good modulators vs. poor 502 
modulators; pBonferroni<0.05] (Fig. 5A,B). The Number Needed to Treat per NF 503 
success subgroups for normalized REM latency, were 3.0 for good modulators and 504 

















3.4 Follow-up clinical outcome and their relation to immediate neurofeedback 508 
effect  509 
To assess the long-term clinical impact of Amyg-EFP-NF treatment, we performed an 510 
unplanned assessment of self-report measurements 16.2±8.72 months following NF 511 
training, focusing on the subjective measures of pain, affect and sleep experience. We 512 
used a repeated measures ANOVA, with time (post-NF/follow-up) as within subject 513 
variable, condition (Amyg-EFP/Sham-EFP) as between subject variable and time 514 
elapsed since the end of the NF training as a covariant.  This analysis demonstrated 515 
that pain and sleep experience were improved at follow-up relative to post-NF only in 516 
the Real-NF group, while affect showed a marginally significant effect (pain: 517 
Time*Condition [F(1,28)=6.7, p<0.05; d=1.1], ;post-hoc for time effect in Real-NF 518 
group, pBonferroni<0.05, sleep experience: Time*Condition [F(1,28)=5.02; p<0.05; 519 
d=0.92] ; post hoc-test for time effect in Real-NF group, pBonferroni<0.05, affect: 520 
Time* Condition [F(1,28)=3.69; p=0.065; d=0.81]) (Fig. 4A-C).  521 
 522 
Lastly, to account for the relation between immediate clinical outcome following 523 
treatment and the long-term effect of pain reduction, we applied moderation analysis 524 
using a custom-made regression model (see methods). This analysis examined the 525 
manner by which immediate homeostasis related outcomes of sleep experience, affect 526 
and composite sleep score predict long-term pain reduction (Fig. 6). This analysis 527 
revealed that improvement in composite sleep score following NF training was 528 
predictive of pain reduction in the follow-up assessment [B=0.91; p=0.01; 95% CI 529 
(0.21, 1.6)]; and that the interaction between improvement in composite sleep score 530 
and subjective affect post NF training had an additional, significant contribution to 531 
the prediction of pain reduction at follow-up [B=1.9; p<0.05; 95% CI (0.19, 3.68)]. In 532 
contrast, self-reported sleep experience did not have any predictive power for long-533 
term pain reduction and was not moderated by objective sleep score. Importantly, 534 
time elapsed from the end of NF training to follow-up assessment was used as a 535 
covariant and did not significantly contribute to the model. These results suggest that 536 
when both objective sleep and affective symptoms were improved initially, pain 537 















strengthening the idea that long-term pain alleviation relies on improvements in 539 
homeostatic indices.   540 
4. Discussion 541 
  542 
The goal of the current study was to utilize a disease-relevant fMRI-based EEG-NF in 543 
a clinical population and to assess NF training effects on somatic-affective 544 
homeostasis measures such as sleep quality, subjective affect and chronic-pain. To 545 
this aim, we applied in a randomized placebo control manner ten sessions of 546 
Amyg-EFP-NF (or sham-NF) in a cohort of Fibromyalgia patients. We were able to 547 
demonstrate improved NF regulation abilities in the real NF group, followed by a 548 
robust immediate improvement in objective measures of sleep quality (NNT for 549 
normalized REM latency was 3.87). Immediately after NF training, we found no 550 
improvement in chronic pain. However, exploratory long-term follow-up conducted 551 
16.2±8.72 months after the completion of the NF course revealed delayed 552 
improvement in chronic pain and sleep experience when compared to the end of 553 
treatment. Importantly, pain improvement at follow-up could be predicted by 554 
improvement in objective sleep observed immediately after NF training and its 555 
interaction with improved affective symptoms. 556 
We have previously shown that healthy individuals can learn to down modulate 557 
the Amyg-EFP signal after short NF training and that this modulation 558 
corresponds to altered BOLD activity of the amygdala (Keynan et al., 2016). 559 
More so, in a recent paper we demonstrate that repeated session of Amyg-EFP-560 
NF result in improved neural as well as behavioral indices of emotion regulation 561 
(Keynan et al., Accepted).  Here, we elaborate this concept by demonstrating that 562 
Fibromyalgia patients are also able to down modulate their Amyg-EFP signal via 563 
repeated NF sessions, thus proving the relevance of our novel imaging approach 564 
to limbic neuromodulation in a clinical set-up.  565 
Markedly, when comparing pre-intervention to follow-up assessment, NNT for 40% 566 
reduction in pain intensity (measured using visual analog scale) was 3.14. This result 567 
indicates relatively high clinical effectiveness, in comparison to common 568 
treatment medication; e.g. Milnacipran was reported to have NNT of 8.5 (Cording 569 
et al., 2015), Duloxetine 7.2, and Pregabalin 8.6 (Bellato et al., 2012). As current 570 















emphasize the value of multimodal interventions (Häuser et al., 2015; Nüesch et al., 572 
2013) these results seems to carry high clinical relevance.  573 
 574 
4.1 Limbic function and chronic pain  575 
In contrast with previous NF studies in the setting of chronic pain (deCharms et al., 576 
2005; Guan et al., 2015), we employed a limbic probe for neuromodulation rather 577 
than targeting a traditional ‘pain matrix’ region (Apkarian et al., 2005). This decision 578 
was informed by accounts suggesting a critical role for the limbic system in chronic 579 
pain. Animal models demonstrated that amygdala hyperactivity generates enhanced 580 
feedforward inhibition of the medial prefrontal cortex, causing impaired cortical 581 
control that supports persistent activation of pain mechanisms (Neugebauer, 2015; 582 
Neugebauer et al., 2004). In humans, structural and functional limbic abnormalities 583 
predict transition from acute to chronic pain (Mansour et al., 2013; Vachon-Presseau 584 
et al., 2016). These findings support the idea that emotional states, underlined by 585 
limbic structures, may play a crucial role not only in  pain perception and modulation, 586 
but also in its chronification (Baliki et al., 2012; Bushnell et al., 2013; Hashmi et al., 587 
2013).  588 
These propositions are nicely integrated in a recent theoretical framework which 589 
ascribes a main role for the limbic system in perceiving and maintaining bodily 590 
homeostasis; sensory information indicating the current state of the body is integrated 591 
in the limbic cortex and projected forward to construct an affect. According to this 592 
approach, aberrant perceptions regarding bodily states may hamper this process and 593 
can therefore cause chronic physical burdens, known as allostatic load, resulting in 594 
mental and physical illnesses such as depression (Barrett et al., 2016)  and chronic 595 
pain (Di Lernia et al., 2016b). Guided by this conceptualization, we aimed to improve 596 
limbic modulation and therefore related homeostatic functions using Amyg-EFP-NF. 597 
Indeed, our results suggest that improved limbic regulation resulted in distinct 598 
clinical improvement in sleep that later manifested in long-term pain relief (see 599 
Fig. 6) 600 
    601 
4.2 Sleep as a mediator in pain treatment 602 
Sleep abnormalities are among the most common complaints in chronic pain in 603 















(Häuser et al., 2008; Yunus, 2007). Often more prominent than pain itself, sleep 605 
disorders have been suggested  to be one of the main processes contributing to pain 606 
chronicity (Choy, 2015; Yunus, 2007).  Accordingly, we found that improvement in 607 
objective indices of sleep immediately after the NF training predicted improvement in 608 
chronic pain during long term follow-up (Fig. 6). Moreover, we demonstrated that 609 
when both objective sleep and affective symptoms were improved at the end of the 610 
NF training, pain at long term follow-up was improved to the largest extent.  611 
These results are in line with prior evidence that effective pharmacological and 612 
nonpharmacological therapies often improve both sleep quality and pain severity in 613 
Fibromyalgia patients.  Treatment with sodium oxybate, a sleep modifier used to treat 614 
narcolepsy, led to improved pain ratings, correlated with decreased  sleep disturbance 615 
(Moldofsky et al., 2010; Russell et al., 2009b; Spaeth et al., 2012). Likewise, 616 
pregabalin, an FDA approved medication for Fibromyalgia also has a beneficial effect 617 
on sleep (Mease et al., 2008; Russell et al., 2009a). Interestingly, some evidence 618 
suggests a positive effect for melatonin, commonly used for sleep aid to support pain 619 
relief in Fibromyalgia (de Zanette et al., 2014; Hussain et al., 2011; Reiter et al., 620 
2007). Further, cognitive behavioral therapy was shown to improve subjective sleep 621 
as well as pain catastrophizing, anxiety and depression (Martínez et al., 2014).  622 
Taken together, these findings support the suggestion that sleep may mediate the 623 
association between emotional symptoms and pain via amygdala functionality; It is 624 
well established that affective disorders such as anxiety and depression are highly 625 
comorbid with sleep dysregulation (Alvaro et al., 2013; Pires et al., 2016; Tsuno et al., 626 
2005). Therefore, it was suggested that impaired sleep triggers unregulated aversive 627 
emotional processing by hampering affect reactivity and emotion regulation 628 
(Anderson and Platten, 2011; Krause et al., 2017; Minkel et al., 2012). Importantly, a 629 
key role is attributed to amygdala dysregulation in this maladaptive emotional 630 
processing, manly via impaired connectivity with the pre-frontal cortex (Goldstein 631 
and Walker, 2014; Motomura et al., 2013; Prather et al., 2013; Simon et al., 2015; 632 
Yoo et al., 2007). Moreover, the amygdala, together with the anterior cingulate cortex 633 
and anterior insula, forms the salience-detection network that mediates discrimination 634 
between stimuli of different emotional strengths. Following insufficient sleep this 635 
network displays non-specific, over generalizing responses to emotional cues 636 
(Goldstein and Walker, 2014). Importantly, structural and functional alterations in 637 















in patients with chronic visceral pain (Mayer et al., 2015), leading to the claim that 639 
chronic pain can be considered, at least in part, as a condition of altered responsive 640 
salience (Borsook et al., 2013). Disordered sleep has also been indicated as 641 
exacerbating pain chronicity by interfering with normal processing of interoceptive  642 
information; enabling awareness to our body state (Craig, 2003; Ewing et al., 2017). 643 
Indeed, a recent paper with Fibromyalgia patients demonstrated that objective sleep 644 
measures mediate the relation between pain intensity and level of anxiety and 645 
depression (Diaz-piedra et al., 2014). Altogether, our results support the idea that 646 
improvements in sleep  may have a beneficial effect on chronic pain by restoring 647 
control mechanisms of homeostasis, which in turn breaks the vicious cycle of chronic 648 
pain, sleep disturbance and mood abnormalities (Choy, 2015). 649 
 650 
 651 
4.3 Clinical perspective of Amyg-EFP-NF 652 
The demonstration that a low-cost mechanism-based EEG-NF treatment can be 653 
clinically valuable in Fibromyalgia patients carries significant hope for this poorly 654 
managed syndrome. As expected, not all patients exhibited the same learning 655 
capacity. Previous reports have linked differences in NF performance to 656 
behavioral/clinical improvement (Kim et al., 2015; Wen et al., 2013; Zuberer et al., 657 
2015), affirming the basic assumption that  NF trains neural regulation, which alters 658 
behavior and improves clinical outcome (Thibault et al., 2017). Here too, we 659 
observed that participants that presented enhanced Amyg-EFP regulation skills 660 
also displayed a more robust sleep related clinical improvement at the end of the 661 
NF training.  662 
Results from the full NF protocol analysis (see Fig. S.1) indicted that some 663 
participants in the Real-NF group were unable to regulate their Amyg-EFP 664 
signal better than sham-group participants. This result corresponds to previous 665 
findings suggested that a significant percent of the population (10-50%) are 666 
unable to influence their brain activity (Alkoby et al., 2017; Allison and Neuper, 667 
2010; Jeunet et al., 2016). In previous studies, NF treatment efficiency was 668 
successfully predicted using behavioral  factors such as control belief (Witte et 669 
al., 2013), motivation, mood (Nijboer et al., 2010, 2008), memory (Daum et al., 670 















resting-state alpha (Wan et al., 2014) or beta (Nan et al., 2015) (for detailed 672 
review see Alkoby et al., 2017). However, in our sample prediction was 673 
unsuccessful using behavioral, neural or clinical factors. Nonetheless, and as has 674 
been previously demonstrated  (Neumann and Birbaumer, 2003; Weber et al., 675 
2011), the first NF session, in this case, of animated scenario, was predictive for 676 
the overall NF regulation abilities (see Fig. 2B). We suggest that this quality might 677 
be due to the more enjoyable, engaging and relatable nature of the animated scenario 678 
interface (Cohen et al., 2016) as well as its multi-modality. As this interface was 679 
deliberately designed to provoke limbic activity and user engagement, we were 680 
pleased to observe that it could effectively predict treatment success.  681 
Importantly, the pattern of clinical change observed here taps into the important 682 
issues of NF’s latent effect (see Fig. 5). This subject was the focus of a recent 683 
study by Rance et al (Rance et al., 2018) that reported, that in two clinical 684 
populations (OCD and Tourette Syndrome), symptoms kept improving up to 80 685 
days from the end of the NF training. The authors point out that a similar 686 
pattern of results is evident in previous NF studies at the behavioral (Amano et 687 
al., 2016), clinical (Schnyer et al., 2015) and neural (e.g Harmelech et al., 2013, 688 
Robineau et al., 2017, Yuan., 2014) levels.  689 
Two mechanisms are suggested to underlie these latent effects. The first is 690 
behavioral: much like other coping skills, such as those acquired by cognitive 691 
behavioral therapy, (also demonstrated to have a latent effect e.g. Carroll et al., 692 
1994; Goldstein et al., 1989; Piacentini et al., 2011)  NF can turn into a skill that 693 
is integrated into daily life. Hence, as time goes by, it is possible that trainees 694 
continue to practice the new skill they acquired and thus symptoms and neural 695 
regulation continue to improve. The second mechanism suggested relates to 696 
neural learning principles: over time, consolidation and reconsolidation 697 
processes that underlie learning paradigms such as NF are likely to take place 698 
(Kandel et al., 2014). As these processes occur regardless of practice, 699 
synchronization, or desynchronization of the targeted brain process may 700 
increase over time (Rance et al., 2018). 701 
The results we report here are consistent with Rance's et al suggestion regarding 702 
the latent effect of NF.  However, our results concern a longer time duration than 703 















Although we controlled for this variable in the relevant analyses by employing it 705 
as a covariate, ideally this should be factored in prospectively.  706 
 707 
Our results also relate to the current discussion regarding the strong placebo effect of 708 
NF intervention (Thibault and Raz, 2017). A recent study that significantly 709 
contributed to this discussion, conducted by Schabus et al, used a full-length, widely 710 
accepted, EEG-NF protocol (increasing 12–15 Hz rhythm over the sensorimotor 711 
cortex) to improve the clinical status of insomnia patients. Results of this study 712 
showed no advantage to NF-treatment over sham treatment  (Schabus et al., 2017). 713 
Similarly, we observed non-differential effect in subjective reports at the end of the 714 
NF training. However, as we targeted a specific neural probe, we witnessed an 715 
immediate effect on objective sleep measures related to NF training success, as well 716 
as long term clinical improvement evident in the Real-NF group only.  717 
 718 
Interestingly, although a connection between modulation success and clinical 719 
outcome was observed, we could not find a correlation between these two 720 
measures. This may echo the suggestion by Ramos‐Murguialday et al. (2013), 721 
that the nature of the relation between NF learning and behavioral/clinical 722 
outcomes should not necessarily be a linear one. Learning to control NF may 723 
follow similar principles as the learning of motor skills. As such, patients may 724 
acquire these “skills” via NF training, which then become part of their 725 
behavioral repertoire. Accordingly, one would expect that the acquisition of the 726 
skill by itself, rather than the level of proficiency, has the crucial effect on clinical 727 
outcomes. 728 
 729 
4.4 Methodological considerations 730 
We acknowledge that certain aspects of this study could be improved and hope 731 
that further research will untangle aspects that remained unsolved. The first 732 
issue is NF learning: In a recent study we demonstrated that trainee were able to 733 
down-modulate their Amyg-EFP signal better than active control after four 734 
Amyg-EFP-NF session (see Keynan et al., Accepted, Fig. 3). However, in the 735 
current study, participants showed improved Amyg-EFP regulation only at the 736 















the unhealthy populations in this study (as was briefly discuss in Schabus et al., 738 
2017) or, alternately, might be due to the combination of different feedback 739 
interfaces that introduced additional challenges. By interleaving two interfaces, 740 
we hoped to provide an engaging training set-up for repeated sessions. However, 741 
in fact, this NF protocol might have disturbed an effective learning. Further, the 742 
relation between NF regulation and clinical outcome could have been better 743 
accounted for using transfer trails, which was unfortunately unavailable. 744 
Moreover, to, fully control for effects of NF-reward related process (Emmert et 745 
al., 2016; Sitaram et al., 2017) it would preferable to use complete matching of 746 
success rates between the sham to real NF. Likewise, we believe that further 747 
studies may apply additional control groups regulating a different brain probe rather 748 
than sham-EFP. Such an approach could help support the claim that targeting a 749 
specific domain, as done using the Amyg-EFP, indeed produces specific and 750 
differential results. Clearly, we hope that the results presented here will be 751 
replicated in a bigger sample size and include more elaborate and quantifiable 752 
measures of pain such as quantitative sensory testing or central pain modulation, that 753 
could potentially better characterize a relation between pain modulation and NF 754 
learning. Lastly, as mentioned, the Amyg-EFP signal represents neural activity in 755 
a network of regions, including limbic and salience related areas (Keynan et al., 756 
2016). Recent results suggest that Amyg-EFP-NF lead to improved amygdala 757 
BOLD modulation and increased connectivity to the vmPFC (Keynan et al., 758 
Accepted). With that, in order to fully account for the relation between amygdala 759 
regulation and improved clinical outcome, fMRI exams in future studies would 760 
be beneficial.  761 
      762 
  763 
5. Conclusions 764 
Using a randomized, double-blind, placebo-controlled design with outcome 765 
measurements of homeostasis (sleep and affect) and pain, and accounting for 766 
measures of learning (good versus poor modulators), we show that Amyg-EFP-NF 767 
can serve as a scalable non-pharmacological, non–invasive treatment for individuals 768 
suffering from Fibromyalgia. By examining the therapeutic potential of limbic 769 















the clinical potential of mechanism-driven fMRI driven EEG-NF approaches that 771 
target specific neural processes relevant to different disease states, thus promising to 772 
be a highly accessible therapeutic tool, both in medical settings as well as in the 773 
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0.16  2M 7F 1M 24F Gender 
0.93 0.08 35.9±10.6 35.5±12.6 Age 
0.9 0.12 4.1±4.4 4.3±4.1 Time from diagnosis (years) 
0.35  33.33 16 SSRI/SNRI (%) 
0.67  33.33 24 Gabapentinoids  (%) 
1  22.22 20 Cannabis (%) 
1  0 8 Analgesics (%) 
1  11 12 Miscellaneous (%) 
0.68 0.41 2.88.73±1.1 2.73±0.9 Pain (VAS, McGill, FIQ pain) 
0.32 1.02 2.84±0.7 2.53±0.7 Affect (STAI-T, BDI, FIQ 
anxiety, FIQ depression) 
0.49 0.69 3.93±1.0 4.17±0.9 Sleep experience (PSQI, FIQ 
fatigue) 
0.34 0.97 90.0±34.5 76.67±35.2 REM latency (min) 
0.17 1.4 0.13±0.28 -0.09±0.43 Composite Sleep Score (sleep 
latency, sleep efficiency, REM 
latency, Deep Sleep percent, 
REM sleep percent) 
 1274 
Table.1, Baseline characteristics of the sample. VAS- visual analog scale, FIQ-1275 
Fibromyalgia Impact Questionnaire, BDI-Beck's Depression Inventory, STAI T-Trait 1276 

















Fig.2, NF learning. a. Effect size for NF learning index in the first and last training 1280 
sessions (black and gray boxes, respectively), per group (Real-NF/sham-EFP), with 1281 
box plot displaying significant interaction of Session*Condition and simple effect of 1282 
session only for the Real-NF group, showing greater learning effect at the last 1283 
session compared to the first. b. Scatterplot of the relation between effect size in 1284 
the first animated scenario session and the average learning effect size across all 1285 
the other sessions (3-10), showing significant positive correlation (r=0.44, 1286 
Rsqr=0.16, p<0.05), thus pointing to a predictive value of the first animated 1287 
scenario session with regard to later NF success. **p <0.005, ***p < 0.0005. 1288 
Bonferroni post hoc correction. This analysis is based on data from 25 real NF 1289 



















 Fig.3, Change in self-report readouts, pre to post assessment. a. Pain readout 1295 
(VAS, McGill general score, FIQ pain) pre/post NF training.  Bar graphs display no 1296 
main effect of time, nor interaction of Time*Condition. b. Affect readout (STAI-T, 1297 
BDI, FIQ anxiety, FIQ depression) pre/post NF training. Bar graphs show simple 1298 
effect for time (pre/post NF) only for the Real-NF group, without Interaction of 1299 
Time*Condition. c. Sleep experience readout (PSQI, FIQ fatigue) pre/post NF 1300 
training. Bar graphs show simple effect for time (pre/post NF) for both groups, 1301 
without Interaction of Time*Condition. Error bars represent SEM. *p < 0.05; **p < 1302 
0.005. Bonferroni post hoc corrections. This analysis is based on data from 33 1303 

















  1307 
Fig.4, Change in self-report readouts, post-NF to follow-up assessment a. Pain 1308 
readout, post NF/ follow-up. Bar graphs show Interaction of Time*Condition and 1309 
simple effect for time (post NF/follow-up) only for the Real-NF group. b. Affect 1310 
readout, post NF/ follow-up. Bar graphs show marginal Interaction of 1311 
Time*Condition (p=0.065) but no simple effect for time (post NF/ follow-up). c. 1312 
Sleep experience readout. Bar graphs show Interaction of Time*Condition and effect 1313 
for time (post NF/ follow-up) only for the Real-NF group. Error bars represent SEM. 1314 
*p <0.05; **p <0.005. Bonferroni post hoc corrections. Values are presented with 1315 
covariate of time from end of the study at level of 15.8 months. This analysis is 1316 
based on data from 31 participants, 22 from the real NF group and 9 from the 1317 

















 Fig.5, Objective sleep changes over time. Difference between post and pre-NF, per 1321 
subgroup (good modulators/poor modulators/sham) a. REM latency. Box plot 1322 
displaying significant effect for group. Post hoc tests show significant difference 1323 
between good modulators and sham.  b. Composite Sleep Score (see methods). Box 1324 
plot displaying significant effect for group. Post hoc tests show significant difference 1325 
between good modulators and sham and between good and poor modulators. *p < 1326 
0.05; **p < 0.005. Bonferroni post hoc corrections. This analysis is based on data 1327 


























Fig.6, Pain improvement in follow-up session: moderation analysis of follow-up 1340 
pain improvement. a. Conceptual Diagram: the moderation model was designed to 1341 
examine how objective sleep improvement, reflected by Composite Sleep Score (see 1342 
methods), predicts long-term pain reduction and how this index moderates the 1343 
contribution of affect and Sleep experience on this pain alleviation. b. Statistical 1344 
illustration of the moderation. This analysis is based on data from 30 participants, 1345 
21 from the real NF group and 9 from the sham NF group.   1346 
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